Key Highlights

  • BIO-B shares traded at $387.06, up 25.11% in today's session, near the top of a 52-week range of $244.54 to $387.10.
  • Bio-Rad's CFO will join a fireside chat at Wells Fargo's 21st Annual Healthcare Conference on September 9, 2026.
  • Second-quarter Revenue reached approximately 651 million dollars against estimates of 624.8 million dollars.
  • Adjusted Earnings Per Share came in at $2.62, above the $1.78 estimate.
  • Market Capitalization stood at approximately 10.59 billion dollars, with a trailing price to earnings ratio of 46.76.

Wells Fargo Conference Appearance Keeps Bio-Rad in Focus

Bio-Rad Laboratories, Inc. (NYSE:BIO-B) shares rose 25.11% in today's Trading session to $387.06 after the company confirmed that Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat during Wells Fargo's 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 3:45 PM Eastern Time. A live webcast and replay will be made available through the Investor relations section of the company's website.

Bio-Rad is a global provider of life science research and clinical diagnostics products, operating through two core segments. Its Life Science segment serves academic, biopharmaceutical, and food safety customers with instruments and reagents, while its Clinical Diagnostics segment supplies testing systems used by hospitals and reference laboratories. The company is based in Hercules, California, and employs approximately 7,400 people worldwide.

The conference appearance arrives as shares trade near the top of their 52-week range, a sharp move from the $244.54 low reached earlier in the year. The stock's advance has coincided with renewed investor attention following the company's most recent quarterly results and ongoing engagement with an activist shareholder.

Earnings Beat Builds the Fundamental Backdrop

Bio-Rad's move builds on a second-quarter earnings report released on August 5, 2026, in which revenue came in at approximately 651 million dollars, ahead of the 624.8 million dollars analysts had projected. Adjusted earnings per share reached $2.62 against an estimate of $1.78. Revenue was roughly flat year over year on a reported basis and down slightly on a currency-neutral basis, though it rose approximately 10% sequentially, with clinical diagnostics returning to modest growth while life science softened on academic research spending and difficult prior-year comparisons.

Digital PCR was cited as a particular area of strength, with currency-neutral revenue in that category up 6% and instrument revenue growing more than 20%, aided by competitive wins for its QX700 platform and the one-year anniversary of its Stilla Technologies acquisition. The company also announced a restructuring program involving headcount reductions and Facility rationalization, targeted for substantial completion by the end of 2027, aimed at generating 30 million to 35 million dollars in annualized net cost savings.

Elliott Management Engagement and Valuation Context

Bio-Rad reaffirmed full-year 2026 guidance calling for currency-neutral revenue growth of negative 3% to positive 0.5%, non-GAAP gross Margin of 53% to 54%, and free Cash Flow of approximately 290 million to 340 million dollars. Management also disclosed constructive engagement with Elliott Management, describing broad alignment on objectives including improved execution, sharper capital allocation, and narrowing the gap between the company's Intrinsic Value and its share price. The company confirmed its stake in Sartorius remains an asset it considers monetizable, with no change to its strategic view on the holding.

Bio-Rad's market capitalization stood at approximately 10.59 billion dollars, with a forward price to earnings ratio of 37.57 and a trailing price to earnings ratio of 46.76. The company reported a 52-week trading range of $244.54 to $387.10.

What Comes Next for Bio-Rad

Bio-Rad's upcoming appearance at the Wells Fargo Healthcare Conference keeps the company in front of investors at a moment when its shares have risen sharply, supported by a second-quarter earnings beat, strength in its digital PCR business, and disclosed engagement with Elliott Management on closing the gap between share price and intrinsic value. Investors will watch the September 9 fireside chat for further detail on capital allocation priorities and the status of the company's restructuring program and Sartorius stake.